Detection and expression of a cDNA clone that encodes a polypeptide containing two inhibitory domains of human calpastatin and its recognition by rheumatoid arthritis sera
- PMID: 7706496
- PMCID: PMC295733
- DOI: 10.1172/JCI117870
Detection and expression of a cDNA clone that encodes a polypeptide containing two inhibitory domains of human calpastatin and its recognition by rheumatoid arthritis sera
Abstract
RA is the most frequent and most destructive inflammatory arthropathy. Rheumatoid factors, in spite of their lack of disease specificity, are important serological markers for RA and appear important in its immunopathogenesis as well. In search of more disease-specific autoimmune systems, we have screened a human placenta lambda gt11 cDNA expression library using selected sera from patients with classical erosive RA. We have identified one clone (RA-1) that is recognized by three of five screening sera. The 950-bp insert shows a complete nucleotide sequence homology to the cDNA encoding the two COOH-terminal domains of calpastatin. The deduced open reading frame of the RA-1 cDNA predicts a 284-amino acid protein, with a calculated mol wt of 35.9 kD. Calpastatin is the natural inhibitor of calpains, which are members of the cysteine proteinases recently implicated in joint destruction in rheumatic diseases. The two domains encoded by the RA-1 clone each contain the structural features associated with the inhibitory activity of human calpastatin. By Western blotting, 45.5% or 21/44 RA sera specifically recognized both the fusion and the cleaved recombinant protein. This is in contrast to 4.7% (2/43) in nonrheumatoid sera and 0/10 in normal sera. Anticalpastatin autoantibodies could represent a disease-associated marker in chronic erosive arthritis of the rheumatoid type and could hypothetically play a dual pathogenic role, directly via an immune interference and indirectly through an immune complex mechanism.
Similar articles
-
[Antigenic epitopes recognized by autoantibodies to calpastatin in patients with rheumatoid arthritis and their clinical significance].Ryumachi. 1997 Jun;37(3):458-66. Ryumachi. 1997. PMID: 9256029 Clinical Trial. Japanese.
-
Autoantibodies to calpastatin (an endogenous inhibitor for calcium-dependent neutral protease, calpain) in systemic rheumatic diseases.Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7267-71. doi: 10.1073/pnas.92.16.7267. Proc Natl Acad Sci U S A. 1995. PMID: 7638179 Free PMC article.
-
Efficient isolation of cDNA clones encoding rheumatoid arthritis autoantigens by lambda phage surface display.J Biotechnol. 2004 Oct 19;114(1-2):55-8. doi: 10.1016/j.jbiotec.2004.05.010. J Biotechnol. 2004. PMID: 15464598
-
[Novel autoantibodies and their target antigens in rheumatoid arthritis].Nihon Rinsho. 2002 Dec;60(12):2263-8. Nihon Rinsho. 2002. PMID: 12510348 Review. Japanese.
-
Rilonacept--CAPS and beyond.Ann N Y Acad Sci. 2009 Dec;1182:124-34. doi: 10.1111/j.1749-6632.2009.05074.x. Ann N Y Acad Sci. 2009. PMID: 20074281 Review.
Cited by
-
Tissue-associated autoantigens in rheumatoid arthritis. Tissue-antigens detected by autoantibodies in synovial fluid and sera of RA patients.Clin Rev Allergy Immunol. 2000 Feb;18(1):59-71. doi: 10.1385/CRIAI:18:1:59. Clin Rev Allergy Immunol. 2000. PMID: 10907108 Review. No abstract available.
-
Antibodies against a novel nucleolar and cytoplasmic antigen (p105-p42) present in the sera of patients with a subset of rheumatoid arthritis (RA) with signs of scleroderma.Clin Exp Immunol. 1998 Nov;114(2):301-10. doi: 10.1046/j.1365-2249.1998.00725.x. Clin Exp Immunol. 1998. PMID: 9822291 Free PMC article.
-
Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset.Arthritis Res. 2000;2(3):236-43. doi: 10.1186/ar93. Epub 2000 Mar 31. Arthritis Res. 2000. PMID: 11056669 Free PMC article.
-
Insights into rheumatoid arthritis derived from the Sa immune system.Arthritis Res. 2000;2(6):429-32. doi: 10.1186/ar122. Epub 2000 Aug 17. Arthritis Res. 2000. PMID: 11094453 Free PMC article. Review.
-
Overexpression of a minimal domain of calpastatin suppresses IL-6 production and Th17 development via reduced NF-κB and increased STAT5 signals.PLoS One. 2011;6(10):e27020. doi: 10.1371/journal.pone.0027020. Epub 2011 Oct 27. PLoS One. 2011. PMID: 22046434 Free PMC article.
References
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases